GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Eric Stier sold 2,750 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $9.60, for a total value of $26,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Eric Stier also recently made the following trade(s):

  • On Tuesday, September 5th, Eric Stier sold 311 shares of GenMark Diagnostics stock. The stock was sold at an average price of $9.75, for a total value of $3,032.25.

GenMark Diagnostics, Inc. (GNMK) traded up 1.46% during mid-day trading on Friday, reaching $9.74. The company’s stock had a trading volume of 231,935 shares. The firm has a 50-day moving average of $9.51 and a 200-day moving average of $11.60. The stock’s market capitalization is $532.46 million. GenMark Diagnostics, Inc. has a 52 week low of $8.88 and a 52 week high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The company had revenue of $12.36 million for the quarter, compared to the consensus estimate of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the company posted ($0.30) earnings per share. On average, equities research analysts expect that GenMark Diagnostics, Inc. will post ($1.07) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “GenMark Diagnostics, Inc. (GNMK) SVP Sells $26,400.00 in Stock” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/genmark-diagnostics-inc-gnmk-svp-sells-26400-00-in-stock/1615500.html.

A number of research firms recently issued reports on GNMK. BidaskClub downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of GenMark Diagnostics in a research report on Wednesday. Bank of America Corporation assumed coverage on GenMark Diagnostics in a research report on Monday, September 18th. They set a “buy” rating and a $13.00 price objective for the company. Cowen and Company reaffirmed an “outperform” rating and set a $17.00 price objective on shares of GenMark Diagnostics in a research report on Wednesday, August 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of GenMark Diagnostics in a research report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. GenMark Diagnostics currently has a consensus rating of “Buy” and a consensus price target of $14.40.

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of GenMark Diagnostics by 15.8% during the second quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider’s stock valued at $48,476,000 after purchasing an additional 559,629 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of GenMark Diagnostics by 62,991.5% during the second quarter. Federated Investors Inc. PA now owns 200,000 shares of the medical equipment provider’s stock valued at $2,366,000 after purchasing an additional 199,683 shares during the last quarter. Marshall Wace North America L.P. grew its holdings in shares of GenMark Diagnostics by 1,787.6% during the second quarter. Marshall Wace North America L.P. now owns 544,020 shares of the medical equipment provider’s stock valued at $6,528,000 after purchasing an additional 515,200 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of GenMark Diagnostics during the first quarter valued at approximately $435,000. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of GenMark Diagnostics during the first quarter valued at approximately $375,000.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.